Anti-interleukin-5 therapy (mepolizumab) in life-threatening asthma attack: A case-based discussion. (2019)

• Record Type: Journal Article
• Authors: Tello, Khodr; Hoffmann, Andreas; Beutel, Björn; Greulich, Timm; Vogelmeier, Claus Franz; Richter, Manuel Jonas; Kuhnert, Stefan; Böselt, Tobias; Alter, Peter; Holland, Angelique; Idzko, Marco; Buhl, Roland; Koczulla, Andreas Rembert
• Is Part Of: Respiratory medicine case reports. Volume 28(2019)
• Publication Date: 2019
• Subjects: Anti-IL-5-therapy -- Asthma -- Eosinophilia -- Exacerbation -- Intensive care medicine; Respiratory organs -- Diseases -- Periodicals; Chest -- Diseases -- Periodicals; Respiratory Tract Diseases -- Periodicals; Respiratory System -- Periodicals; Chest -- Diseases; Respiratory organs -- Diseases; Electronic journals; Periodicals; 616.2
• DOI: 10.1016/j.rmcr.2019.100927
• Languages: English
• ISSNs: 2213-0071

Abstract

Abstract: We report about a case of a compassionate off-label use of the anti-interleukin-5-agent mepolizumab in a ventilated patient with life-threatening asthma attack in eosinophilic asthma. The patient suffered from severe eosinophilic asthma and was transmitted to our hospital with an asthma attack and a life-threatening respiratory state under ventilation. Since high dose steroids had not yielded a sufficient respiratory improvement mepolizumab was administered subcutaneously. After administration of mepolizumab respiratory state and ventilation parameter improved significantly. Two days after administration the patient was weaned could be extubated 8 days later and recovered completely from the asthma attack. The presented clinical case is suggestive of future clinical trials or registry studies to evaluate potential clinical benefits of anti-interleukin-5 treatment in patients with severe exacerbations of eosinophilic asthma.